Actively Recruiting
Kidney and Blood Pressure Outcomes in Childhood Cancer Survivors: Prospective Study of Late Effects after Nephrotoxic Chemotherapies
Led by The Hospital for Sick Children · Updated on 2024-04-17
500
Participants Needed
1
Research Sites
531 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to better understand kidney and blood pressure problems in childhood cancer survivors (CCS), who face higher risks of chronic kidney disease (CKD), hypertension (HTN), and reduced quality of life due to prior cancer treatments. The study focuses on when and how CKD and HTN begin after cancer therapy and seeks to fill gaps in current guidelines that lack clear recommendations for kidney and blood pressure monitoring in CCS. Researchers will observe 500 CCS who received therapies known to affect kidney and blood pressure health. They will assess kidney function and blood pressure at 3 and 5 years after completing cancer treatment. The study will measure kidney filtration rates, protein levels in urine, and blood pressure using both office and ambulatory monitoring. The study also examines the impact of acute kidney injury during treatment and cardiometabolic risk factors on later kidney health. Participants will undergo evaluations at 3 and 5 years post-therapy, including blood and urine tests and blood pressure measurements. Changes in these health markers between these time points will be tracked. The main measures include the prevalence of CKD and HTN at each time point and changes over time. The study aims to provide data to improve international guidelines for kidney and blood pressure monitoring and treatment in CCS, potentially enhancing their long-term health and quality of life.
CONDITIONS
Brief Title
KIdney aNd blooD prESsure ouTcomes in Childhood Cancer Survivors (CCS)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 3 years ± 6 months after first cancer therapy completion
- Received high-risk therapy for first cancer such as alkylating agents, platinums, abdominal or total body radiation, high dose methotrexate, stem cell transplant, nephrectomy, or other therapies possibly causing late kidney or blood pressure effects
You will not qualify if you...
- Severe chronic kidney disease or previous kidney transplant before cancer
- Older than 19 years at 3 years after cancer therapy completion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 years
Participants are observed to assess kidney and blood pressure health at 3 and 5 years after cancer therapy.
2 visits at approximately 3 and 5 years post cancer therapy
Trial Site Locations
Total: 1 location
1
The Hospital For Sick Children
Toronto, Ontario, Canada, M5G 1E8
Actively Recruiting
Research Team
M
Michael Zappitelli, MD
Y
Yasmine Hejri-Rad, BA
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here